Kronn, D., Davison, J., Brassier, A., Broomfield, A., Hahn, S. H., Kumada, S., … Kishnani, P. S. (2022). Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline. In Molecular Genetics and Metabolism (Vol. 135, pp. S68–S68). Elsevier BV. https://doi.org/10.1016/j.ymgme.2021.11.171

Kronn, David, James Davison, Anaïs Brassier, Alexander Broomfield, Si Houn Hahn, Satoko Kumada, François Labarthe, et al. “Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline.” In Molecular Genetics and Metabolism, 135:S68–S68. Elsevier BV, 2022. https://doi.org/10.1016/j.ymgme.2021.11.171.

Kronn D, Davison J, Brassier A, Broomfield A, Hahn SH, Kumada S, et al. Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline. In: Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S68–S68.

Kronn, David, et al. “Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline.” Molecular Genetics and Metabolism, vol. 135, no. 2, Elsevier BV, 2022, pp. S68–S68. Crossref, doi:10.1016/j.ymgme.2021.11.171.

Kronn D, Davison J, Brassier A, Broomfield A, Hahn SH, Kumada S, Labarthe F, Ohki H, Prakalapakorn SG, Haack KA, Meng X, Sparks S, Tammireddy S, Wilson C, Zaher A, Zhou T, Chien Y-H, Kishnani PS. Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline. Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S68–S68.